Recent Finacing
Recent Raise
Rallybio develops antibodies, proteins and small molecules for rare maternal–fetal and immune‑inflammatory diseases, advancing clinical‑stage anti‑HPA‑1a antibody RLYB212 and hyperimmune globulin RLYB‑211.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Rallybio.
